Literature DB >> 18220915

Mesenchymal stromal cells from umbilical cord blood.

Karen Bieback1, Harald Klüter.   

Abstract

Mesenchymal Stromal Cells (MSC) are key candidates for cellular therapies. Although most therapeutic applications have focused on adult bone marrow derived MSC, increasing evidence suggests that MSC are present within a wide range of tissues. Umbilical cord blood (CB) has been proven to be a valuable source of hematopoietic stem cells, but its therapeutic potential extends beyond the hematopoietic component suggesting regenerative potential in solid organs as well. There is evidence that other stem or progenitor populations, such as MSC, exist in CB which might be responsible for these effects. Many different stem and progenitor cell populations have been postulated with potential ranging from embryonic like to lineage-committed progenitor cells. Based on the confusing data, this review focuses on a human CB derived, plastic adherent fibroblastoid population expressing similar characteristics to bone marrow derived MSC. It concentrates especially on concepts of isolation and expansion, comparing the phenotype with bone marrow derived MSC, describing the differentiation capacity and finally in the last the therapeutic potential with regard to regenerative medicine, stromal support, immune modulation and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18220915     DOI: 10.2174/157488807782793763

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  55 in total

1.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

2.  Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology?

Authors:  Ulrich Lindner; Jan Kramer; Jürgen Rohwedel; Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2010-03-15       Impact factor: 3.747

3.  [Mesenchymal stem cells for bone tissue engineering].

Authors:  R K Schneider; S Neuss; R Knüchel; A Perez-Bouza
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

Review 4.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

Review 5.  Mesenchymal stem cells: the fibroblasts' new clothes?

Authors:  Muzlifah A Haniffa; Matthew P Collin; Christopher D Buckley; Francesco Dazzi
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

Review 6.  Cellular therapy of systemic sclerosis.

Authors:  Jacob M van Laar; Alan Tyndall
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 7.  Cord blood--an alternative source for bone regeneration.

Authors:  Marcus Jäger; Christoph Zilkens; Bernd Bittersohl; Rüdiger Krauspe
Journal:  Stem Cell Rev Rep       Date:  2009-08-04       Impact factor: 5.739

8.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

9.  CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Authors:  Selim Kuçi; Zyrafete Kuçi; Hermann Kreyenberg; Erika Deak; Kathrin Pütsch; Sabine Huenecke; Chandrasekhar Amara; Stefanie Koller; Eva Rettinger; Manuel Grez; Ulrike Koehl; Hatixhe Latifi-Pupovci; Reinhard Henschler; Torsten Tonn; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

10.  Mesenchymal stem-like cells isolated from human esophageal carcinoma and adjacent non-cancerous tissues.

Authors:  Jiabo Hu; Zhongwei Zhou; Shunbin Shi; Xiaozhong Zhu; Xiaohui Wang; Wei Zhang; Sanqiang Hu; Hui Qian; Wenrong Xu
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.